Stockwinners Market Radar for May 31, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:32 EDT McKesson CFO sells $9.1M in common stock - In a regulatory filing, McKesson disclosed that its CFO Britt Vitalone sold 27.3K shares of common stock on May 27th in a total transaction size of $9.1M.

18:37 EDT Eve Holding partners with Porsche consulting on eVTOL strategy - Eve Holding (EVEX), a carve-out from Embraer (ERJ), announced that it has chosen Porsche Consulting to help define the eVTOL supply chain, global manufacturing and logistics macro strategy. Considering advanced manufacturing research and innovation, the companies will combine their aeronautic and automotive expertise to support Eve's implementation plan. The master services agreement that has been entered into by and between the companies includes studies on industrial operation, logistics, supply chain and parts distribution in an unprecedented approach optimized for efficiency, productivity and safety.

18:11 EDT Kymera's treatment of Peripheral T-cell Lymphoma granted orphan designation - According to a post on the FDA's website, Kymera Therapeutics' treatment of Peripheral T-cell Lymphoma was granted orphan designation. Reference Link

17:44 EDT Rivian Automotive director buys $1.17M in common stock - In a regulatory filing, Rivian Automotive disclosed that its director Jay Flatley bought 40K shares of common stock on May 26th in a total transaction size of $1.17M.

17:21 EDT Spirit Airlines disagrees with ISS recommendation on proposed deal with Frontier - Spirit Airlines (SAVE) commented on a report from Institutional Shareholder Services regarding the company's definitive merger agreement with Frontier Group Holdings (ULCC), parent company of Frontier Airlines. "We disagree with ISS' recommendation against the Frontier-Spirit merger, which we continue to believe is in the best interest of Spirit stockholders. ISS appears overfocused on the absence of a reverse termination fee in that deal, and we have consistently maintained (as ISS also acknowledges) that the JetBlue proposal carries significantly greater regulatory obstacles, and JetBlue absolutely should pay Spirit stockholders more to compensate for that risk," said Ted Christie, President and CEO of Spirit. "During the extensive discussions held between Spirit and JetBlue, JetBlue admitted that a lawsuit from DOJ seeking to block a merger with Spirit was a 100% certainty; therefore, JetBlue would have to prevail in or settle DOJ litigation in order to consummate the deal. Moreover, ISS did not recognize the elevated business disruption that Spirit would face from a lengthy review and litigation process ultimately resulting from a failed transaction with JetBlue after 18-24 months, nor did it adequately weigh the loss of substantial value Spirit stockholders otherwise would have received in a merger between Spirit and Frontier. We continue to believe the reverse termination fee is a moot point because there is nothing stopping JetBlue from walking away after achieving their goal of disrupting the Spirit-Frontier combination. Further, we disagree with ISS' characterization that stockholders can reinvest the cash proceeds from a JetBlue transaction to maintain exposure to the airline industry recovery. Spirit stockholders would not receive $30 of cash per share for up to two years, if ever, during which time the airline industry recovery may have delivered value for stockholders that far exceeds JetBlue's capped, inadequate and highly opportunistic offer. In contrast, the Frontier combination presents a compelling value creation opportunity due to the combination of cash and stock consideration, which gives our stockholders the chance to participate in the upside of the post-pandemic recovery in the airline industry upon close and benefit from up to $500 million in annual run-rate operating synergies. ISS also recommends Spirit stockholders do not vote JetBlue's proxy card, indicating ISS still sees a potential path forward for Spirit to merge with Frontier. Overall, we ask our stockholders not to be distracted by JetBlue's highly conditional tender offer, and our Board continues to unanimously recommend that Spirit stockholders vote FOR the merger proposal with Frontier," said Christie.

17:02 EDT Laredo Petroleum announces $200M share repurchase program - Laredo Petroleum announced that its board of directors authorized a $200M share repurchase program. The two-year program is authorized through May 27, 2024. Highlights: $200M share repurchase program realizes the company's commitment to begin returning significant cash to shareholders approximately nine months ahead of schedule; Debt repayment target updated to ~$700M by year-end 2023; On track to achieve targeted Net Debt/Consolidated EBITDAX1 ratio target of 1.0x by first-quarter 2023; Free Cash Flow for 2022-23 estimated at ~$900M at current commodity prices.

16:58 EDT Overstock.com up 2.5% at $31.77 after Simcoe disclosed 5.7% stake

16:56 EDT Digital Turbine delays 10-K filing - In a regulatory filing, the company said, "As previously announced, Digital Turbine consummated two significant strategic acquisitions during the fiscal year ended March 31, 2022. In addition, the company filed amended Form 10-Q/As for the quarterly and year-to-date periods ended June 30, 2021, September 30, 2021, and December 31, 2021, on May 27, 2022 related to the previously-disclosed restatement of financial statements during such periods. The inclusion of the acquisitions in the audit of the company's Annual Report on Form 10-K for the fiscal year-ended March 31, 2022 and the filing of the Form 10-Q/As have utilized significant internal resources, which has impacted the company's ability to provide all the necessary information to their auditors for them to complete the audit. As a result, the Form 10-K cannot be filed within the required time period. The company expects to file the Form 10- K within the fifteen-calendar day grace period, as provided by Rule 12b-25 of the Securities Exchange Act of 1934. As disclosed in the company's Form 10-Q/As filed with the SEC on May 27, 2022, the company has identified a material weakness in its internal control over financial reporting related to the presentation of certain revenue net of license fees and revenue share expense and the classification of certain hosting costs. Although the company's management is still in the process of assessing the effectiveness of internal control over financial reporting as of March 31, 2022, the company expects to report such material weakness in the company's internal control over financial reporting in the Form 10-K, and to therefore conclude that the company did not maintain effective internal control over financial reporting and disclosure controls and procedures as of March 31, 2022."

16:52 EDT Intellicheck receives not in compliace letter from Nasdaq - Intellicheck announced that it received on May 24, a written notice from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it was not in compliance with the requirements of Nasdaq Listing Rule 5250 as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31. The Notice has no immediate effect on the listing or trading of Intellicheck's common stock on the Nasdaq CStock Market. Under the Nasdaq Rules, the Company has 60 calendar days to file the Q1 Form 10-Q with the SEC or submit a plan to regain compliance with Rule 5250. Intellicheck currently anticipates that it will file the Q1 Form 10-Q within the next 10 days, and at such time will regain compliance with Nasdaq Listing Rule 5250.

16:38 EDT Univar appointed distributor of Cabot's specialty carbon black product in Brazil - Univar Solutions (UNVR) "announced it has been appointed as distributor of Cabot Corporation's (CBT) specialty carbon black products for the plastics and batteries markets in Brazil. The agreement builds on the companies' existing relationship and will provide customers with innovative materials and solutions that help improve sustainability and product performance."

16:32 EDT Flowers Foods COO Bradley Alexander to retire, Heeth Varnedoe to succeed - Flowers Foods announced that effective December 31, 2022, Bradley Alexander, COO, will retire from the company after 41 years of service. Consistent with the company's management succession plan, on January 1, 2023, Heeth Varnedoe, the company's current chief transformation officer, will succeed Alexander as COO.

16:21 EDT Salesforce reports Q1 cRPO up 21% y/y at $21.5B

16:18 EDT Six Flags names Gary Mick as new CFO - Six Flags "announced that it has appointed Gary Mick as Chief Financial Officer effective June 1, 2022. In his new role, Mr. Mick will have responsibility for the company's financial strategy, budgeting, accounting, financial reporting, audit, tax and capital planning functions. Steve Purtell, who has filled the CFO position on an interim basis since March 2022, will continue to serve as Senior Vice President, Corporate Communications, Investor Relations and Treasurer, reporting to Selim Bassoul, President and CEO."

16:17 EDT VICI Properties names Kellan Florio as Chief Investment Officer - VICI Properties announced the appointment of Kellan Florio, Senior Vice President, Chief Investment Officer and Moira McCloskey, Vice President, Capital Markets. Mr. Florio will be responsible for leading VICI's expansion across experiential real estate investments with world class operators, reporting to John Payne, President and Chief Operating Officer. Ms. McCloskey will be responsible for leading VICI's capital markets initiatives and continuing to expand VICI's relationships and access to capital across domestic and international debt and equity markets, reporting to David Kieske, Executive Vice President, Chief Financial Officer.

16:14 EDT Heritage Global appoints Brian Cobb CFO - Heritage Global announced that VP of Finance Brian Cobb has been appointed CFO, effective immediately. As CFO, Cobb will be responsible for all financial activities including accounting, financial reporting, planning and analysis, investor relations, mergers and acquisitions, taxes, and treasury to support the company's overall growth objectives. Cobb joined the Heritage team in 2017 as the Director of Financial Reporting, with extended responsibilities to manage corporate and divisional accounting functions and personnel.

16:13 EDT Meta Platforms to change ticker symbol to 'META' on June 9 - Meta Platforms announced that its Class A common stock will begin trading on NASDAQ under the ticker symbol 'META' prior to market open on June 9. This will replace the company's current ticker symbol 'FB', which has been used since its initial public offering in 2012. The new ticker symbol aligns with the company's rebranding from Facebook to Meta, announced on October 28, 2021.

16:09 EDT ICF International partners with Google Cloud - ICF (ICFI) is partnering with Google Cloud (GOOG, GOOGL) to expand its cloud and analytics services to public sector clients. ICF's partnership with Google Cloud illustrates ICF's success in accelerating digital transformation for federal agencies on Google Cloud's platform, which includes supporting federal health clients such as the National Cancer Institute and many others. The partnership further expands the company's digital and partnership ecosystem in support of its multi-cloud strategy. Combining ICF's deep domain and technology consulting expertise with new Google Cloud capabilities enhances ICF's capabilities to rapidly deploy digital solutions that advance our customers' missions and increase operational efficiency.

16:06 EDT Meta Platforms to change ticker symbol to 'META' on June 9 - Meta Platforms announced that its Class A common stock will begin trading on NASDAQ under the ticker symbol 'META' prior to market open on June 9. This will replace the company's current ticker symbol 'FB', which has been used since its initial public offering in 2012. The new ticker symbol aligns with the company's rebranding from Facebook to Meta, announced on October 28, 2021.

16:00 EDT Arqit Quantum trading resumes

15:45 EDT Real Good Food Company Inc trading resumes

15:38 EDT Netflix says 'Stranger Things' had record English language premiere weekend - Netflix tweeted: "Stranger Things 4 has been running up that hill since Friday, becoming the biggest premiere weekend ever for an English language TV show on Netflix with 286.79 million hours viewed globally! It also skyrocketed to the 001 spot in 83 countries - another premiere weekend record!" Reference Link

15:20 EDT Xcel Brands trading resumes

14:59 EDT Xcel Brands trading halted, news pending

13:50 EDT SpartanNash says Glass Lewis recommends vote for company's director nominees - SpartanNash announced that independent proxy advisory firm Glass Lewis & Co has recommended that shareholders vote "for" all of SpartanNash director nominees on the white proxy card at the company's 2022 Annual Meeting of Shareholders scheduled for June 9. Commenting on the Glass Lewis report, SpartanNash issued the following statement: "We are pleased that Glass Lewis supports voting on the WHITE proxy card to elect all nine of the company's highly qualified director nominees and clearly recognizes that SpartanNash has the right Board and the right strategy to continue to deliver enhanced value for shareholders. Further, Glass Lewis recognizes that Macellum and Ancora have not offered a sufficiently compelling case to warrant supporting their nominees and that electing their nominees would deprive SpartanNash of skills and expertise that are essential to continuing the company's momentum."

13:18 EDT ZK International portfolio company announces partnership with Nicki Minaj - Shares of ZK International Group are up 26%, or 33c, to $1.60 after the company announced that Nicki Minaj has agreed to a sports betting multi-year, global partnership with MaximBet, a ZKIN portfolio company. ZKIN has invested $25M into MaximBet and currently owns 16% of the company, ZK International noted in its press release announcing the pact. MaximBet is currently live in the state of Colorado and is on track to launch in nine additional U.S. states and the Canadian province of Ontario, the company noted. "Nicki Minaj is one of the most iconic and influential entertainers in the world. The conversion of entertainment and sport is happening at warp speed, and we've built a brand that can appropriately stand at the center of that. Nicki's business experience and relationships open a wealth of opportunity for MaximBet and her involvement as an owner will allow us to work together on decisions in all parts of the business," said Daniel Graetzer, CEO, MaximBet.

12:01 EDT Spirit AeroSystems announces long-term strategic partnership with Sierra Space - Sierra Space and Spirit AeroSystems announced the formation of a long-term strategic partnership intended to "accelerate access to a vibrant commercial space economy of the future." The companies said: "Spirit Defense & Space will assist in the development and production of future affordable Shooting Star Transport Vehicles under a Letter of Intent signed between the two companies. The agreement also provides for the two companies to work together to develop innovative technologies and processes to accelerate Sierra Space's expanding Dream Chaser family of scalable spaceplanes to the market."

12:00 EDT Frontline falls -14.0% - Frontline is down -14.0%, or -$1.60 to $9.83.

12:00 EDT Bakkt rises 14.5% - Bakkt is up 14.5%, or 39c to $3.04.

12:00 EDT CatchMark Timber rises 42.2% - CatchMark Timber is up 42.2%, or $3.50 to $11.80.

10:55 EDT ISS recommends Spirit shareholders 'vote no' on Frontier transaction - JetBlue (JBLU) announced that Institutional Shareholder Services has issued a report recommending that Spirit (SAVE) shareholders vote AGAINST the "inferior, high-risk, and low-value" Frontier (ULCC) transaction at Spirit's upcoming special meeting. "We are pleased that ISS recognized that our proposal offers Spirit shareholders superior value and has a clear path to completion," said Robin Hayes, CEO, JetBlue. "The ISS report highlights the flawed process that the conflicted Spirit Board followed, which only underscores the need for Spirit's Board to now come to the table and negotiate - this time in good faith - with JetBlue. Spirit shareholders can send that strong message to their Board by voting against the Frontier transaction and against adjournment. The ISS report highlighted: "The offer from JetBlue is superior from a financial standpoint, with a cash consideration at a meaningfully higher premium than the mostly stock deal from Frontier ... On balance, a potential agreement with JetBlue would appear to offer shareholders superior optionality, allowing those concerned with the turbulence ahead to exit at a significant premium, while allowing those with a more optimistic outlook to reinvest the premium consideration."

10:33 EDT Blink Charging unit to deploy 600 charging points in U.K., Ireland - EB Charging, a Blink Charging wholly owned company, announced an agreement with Q-Park, a parking infrastructure owner and operator in Europe, to deploy nearly 600 charging points across 80 sites in the United Kingdom and Ireland. The agreement, totaling over GBP 3M, or more than $3.7Mn, will initiate EB Charging's rollout of over 600 charging points across Q-Park's portfolio of parking facilities in the UK and Ireland. Installations are due to commence in July 2022 and will include the modernization of the existing charging infrastructure with EB Charging's hardware. As part of this agreement, EB Charging will be responsible for the installation of the EV charging hardware and for the management of the charging provision, including a 24/7 customer support service to Q-Park EV customers.

10:00 EDT Frontline falls -13.2% - Frontline is down -13.2%, or -$1.51 to $9.92.

10:00 EDT Nine Energy Service rises 12.8% - Nine Energy Service is up 12.8%, or 41c to $3.65.

10:00 EDT CatchMark Timber rises 41.0% - CatchMark Timber is up 41.0%, or $3.40 to $11.70.

09:52 EDT Intergrated Media Technology Ltd trading halted, volatility trading pause

09:47 EDT Frontline falls -12.8% - Frontline is down -12.8%, or -$1.47 to $9.96.

09:47 EDT Ecopetrol rises 11.8% - Ecopetrol is up 11.8%, or $1.80 to $17.11.

09:47 EDT CatchMark Timber rises 42.0% - CatchMark Timber is up 42.0%, or $3.49 to $11.79.

09:44 EDT BioMarin delays hemophilia FDA submission to end of September - BioMarin said it plans to include the previously reported results from the two-year follow-up safety and efficacy data from the Phase 3 GENEr8-1 study in a Biologics Licensing Application resubmission for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, to the Food and Drug Administration. Based on recent feedback received from the FDA related to BioMarin's plans for the upcoming BLA, the Agency has requested additional information and analyses of data to be included in the BLA prior to submission, the company noted in a press release. The FDA has not requested additional pre-clinical or clinical studies. "While at present, no requests have been made concerning evaluation of efficacy and safety three years after dosing from the GENEr8-1 study, BioMarin is aware that such data will become available during the anticipated BLA review. Based on these new information requests, the BLA resubmission is now expected by the end of September," the company said. Shares of BioMarin are down 3% to $78.89 in early trading.

09:36 EDT SGML Stock trading halted, volatility trading pause

09:30 EDT JE Cleantech Holdings Ltd trading halted, volatility trading pause

09:19 EDT Tyler Technologies acquires Quatred, terms undisclosed - Tyler Technologies announced it has acquired Quatred, a systems integrator and solution provider that assists clients with implementing advanced touchless technologies, including barcoding. Quatred has been a Tyler partner since 2018, when Tyler began integrating with Quick, a wireless, service-oriented architecture foundation, providing rapid deployment. These mobile solutions interact in real-time with Tyler's Enterprise ERP solution, powered by Munis, to track assets and inventory transactions. Through this acquisition, Tyler will integrate Quatred's barcoding technology into additional Tyler solutions. Founded in 2005 by Marc Doyon, Quatred is based in Center Barnstead, New Hampshire. The company's employees will join Tyler as full-time employees.

09:14 EDT Bowlero acquires bowling centers in Florida, Colorado - Bowlero Corp. announced that it has acquired two additional bowling centers - Manatee Lanes in metro Tampa, FL and Fat Cats in Westminster, CO. Bowlero Promenade will mark the company's 13th location in Colorado, joining seven Bowlero centers and five AMF centers in the state.

09:12 EDT Chart Industries provides ESG update - Chart Industries provides an update to their environmental, social and governance, ESG, and sustainability progress. Effective as of its Annual Shareholder Meeting, ASM, on May 13, 2022, Singleton McAllister is the company's independent Chairwoman of our Board of Directors. Also effective as of our ASM, the board is comprised of seven directors; six directors are independent and four are female. Received our American Society of Mechanical Engineers XII certificate at our Theodore, Alabama facility effective May 20, 2022. Six additional Engineering Key Experts. Seven new Emerging Leaders. Two newly dedicated Emerging Leaders to our Lean/Continuous Improvement Center of Excellence. Implemented a dedicated team to energy management.

09:10 EDT Caterpillar announces project for hydrogen-fueled CHP system - Caterpillar announced a three-year project with Minnesota-based District Energy St. Paul to demonstrate a hydrogen-fueled combined heat and power, or CHP, system. The project is supported and partially funded by the U.S. Department of Energy and backed by the National Renewable Energy Laboratory. CHP systems from Caterpillar provide both electricity and heat simultaneously, increasing overall efficiency and reducing exhaust emissions. To assess the potential of a hydrogen-fueled CHP system under real-world operating conditions, power and heat from the demonstration project will integrate into District Energy St. Paul's electrical and thermal infrastructure. District Energy St. Paul distributes chilled water and hot water to heat and cool buildings and single-family homes in downtown St. Paul, Minnesota, and adjacent areas.

09:10 EDT Silk Road Medical secures up to $250M in debt financing - Silk Road Medical announced that it has entered into a new five-year loan arrangement with Oxford Finance LLC comprising up to a $200M term loan and up to a $50M revolving line of credit. The transaction brings the company's total cash, cash equivalents, and access to liquidity to approximately $340M. "We are tremendously pleased to bolster our capital position through this financing, substantially enhancing our runway to invest for growth," said Lucas Buchanan, CFO and COO of Silk Road Medical. "This agreement provides additional financial flexibility at very favorable cost and terms in today's environment, including a capped interest rate through maturity. We look forward to leveraging this facility to strengthen our organization as we continue driving TCAR adoption and advancing the less invasive standard of care in stroke prevention."

09:08 EDT Franklin Templeton to acquire Alcentra from BNY Mellon in accretive transaction - Franklin Resources (BEN) a global investment management organization operating as Franklin Templeton, and The Bank of New York Mellon (BK) announced that Franklin Templeton has entered into a definitive agreement to acquire BNY Alcentra Group Holdings from BNY Mellon. One of the largest European credit and private debt managers, Alcentra has $38B in assets under management with global expertise in senior secured loans, high yield bonds, private credit, structured credit, special situations and multi-strategy credit strategies. Through this acquisition, Franklin Templeton's U.S. alternative credit specialist investment manager, Benefit Street Partners , will expand its alternative credit capabilities and presence in Europe, doubling its assets under management to $77B globally. The transaction will also continue to strengthen the breadth and scale of Franklin Templeton's alternative asset strategies and brings firmwide alternative assets under management to $257B after the transaction closes. The transaction is expected to be completed early in the first calendar quarter of 2023, subject to customary closing conditions, including certain regulatory approvals. The acquisition will be funded from Franklin Templeton's existing balance sheet resources and is expected to be immediately accretive to adjusted earnings per share. Franklin Templeton will pay $350 million in cash at close and up to a further $350 million in contingent consideration dependent on the achievement of certain performance thresholds over the next four years. In addition, Franklin Templeton has committed to purchase all seed capital investments from BNY Mellon related to Alcentra which, as of March 31 , were valued at approximately $305M. The seed capital investments will be valued at the time of close to determine the final seed capital purchase amount. An investor presentation on the transaction is available via investors.franklintempleton.com. Upon closing, BNY Mellon Investment Management will continue to offer Alcentra's capabilities in BNY Mellon's sub-advised funds and in select regions via its global distribution platform, and BNY Mellon will provide Alcentra with ongoing asset servicing support. At close, BNY Mellon expects the transaction to increase BNY Mellon's Common Equity Tier 1 capital by approximately $0.5B

09:06 EDT Black Knight announces strategic alliance with Percy - Black Knight announced a strategic alliance with Nashville-based Percy, formerly known as Buyside, a data analytics and marketing company that collects and analyzes real estate consumer behavior using machine learning and artificial intelligence. The alliance will allow Black Knight to offer clients a new, advanced consumer engagement solution fueled by billions of behavioral datapoints that helps real estate professionals and lenders cultivate deeper customer relationships. Using proprietary machine learning to monitor homeowner behavior "signals" through custom landing pages with engaging content, Percy helps identify the precise timing that a homeowner is likely to transact.

09:04 EDT Stryker receives FDA clearance for Q guidance system for spine applications - Stryker announced that its Q Guidance System received 510k clearance from the U.S. Food and Drug Administration. The System, when used with the Spine Guidance Software, is an advanced planning and intraoperative guidance system designed to enable open or percutaneous computer-assisted surgery. The Spine Guidance Software is the first spine navigation software to receive clearance from the FDA for use with pediatric patients aged 13 and older. Stryker's Q Guidance System aims to deliver surgical spine planning and navigation capability through multiple tracking options, sophisticated software algorithms and smart instrumentation. It features a high-performance navigation camera built on the company's 20 years of experience developing guidance technologies. Q Guidance features completely redesigned software applications, semi-automatic and automatic segmentation features, gesture recognition, and broad compatibility with various types of image sets. When used with Airo TruCT mobile CT scanner, this ecosystem delivers automatic image registration and pairs high performance tracking capabilities with cutting edge intraoperative image quality and scan volume. "The versatility of the Q Guidance System will help to streamline our technologies across multiple specialties such as cranial, spine, ENT and orthopaedics," said Robbie Robinson, President of the Spine division. "The System is designed for future compatibility with a fully integrated ecosystem, driving more value for our customers. With a robust product pipeline in place, we are positioned to provide a well-rounded, end-to-end platform for our surgeon customers, with the ability to incorporate robotics and intelligent handheld instruments in the future."

09:02 EDT Amgen reports data from Phase 2 OCEAN-DOSE clinical study - Amgen announced positive topline data from the Phase 2 OCEAN-DOSE clinical study, evaluating olpasiran in 281 adult patients with Lipoprotein, or Lp, levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease, or ASCVD. Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein, a key component of Lp that has been associated with an increased risk of cardiovascular events. In the double-blind placebo-controlled treatment period, olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline Lp of approximately 260 nmol/L. These data demonstrated a significant reduction from baseline in Lp of up to or greater than 90% at week 36 and week 48 for the majority of doses. No new safety concerns were identified during this treatment period.Data from the Phase 2 study will be presented at a future medical congress and submitted for publication.

08:48 EDT Robinhood to settle customer lawsuit over 2020 outage, Reuters reports - Robinhood Markets has agreed to settle a customer lawsuit over a March 2020 outage of its trading app, Reuters' Jody Godoy reports. A court filing shows that the company is working out final details of the settlement, but did not say how much Robinhood would pay to resolve the lawsuit. Reference Link

08:44 EDT Sanofi Rx-to-OTC switch AUT for Cialis placed on clinical hold by FDA - The FDA has informed Sanofi that its planned Actual Use Trial , or AUT, to support the Rx-to-OTC switch for Cialis has been placed on clinical hold due to matters surrounding the protocol design. Sanofi's AUT has not yet recruited any patients. Sanofi continues to work with FDA to move the Cialis program forward and will engage the Agency in upcoming meetings as we determine next steps.

08:40 EDT GrowLife: Dave Dohrmann to succeed Marco Hegyi as CEO - GrowLife announced that company President Dave Dohrmann will assume the role of CEO of GrowLife. The change is set to become effective on July 1, 2022, following the departure of CEO Marco Hegyi. Dohrmann will also be replacing Marco Hegyi on the GrowLife board of directors. Dohrmann has served as the Company President since December 2021.

08:39 EDT SciSparc announces collaboration agreement with Polyrizon - SciSparc announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays. As part of the collaboration, the two companies will work to develop a unique technology for the treatment of pain, based on SciSparc's SCI-160 platform and Polyrizon's Trap and Target intranasal drug delivery technology to target the central nervous system.

08:37 EDT A2Z Smart Technologies enters strategic partnership with Accenture Italy - A2Z Smart Technologies (AZ) announced that it has entered, through its subsidiary and its European partners, into a partnership agreement with Accenture Italy (ACN) to increase the brand recognition and expand the market presence of the Cust2Mate Smart Cart Platform in Europe. A2Z's state-of-the-art Cust2Mate Smart Cart provides a contactless and convenient shopping experience by recognizing every purchased item and enabling in-cart payment so that shoppers don't have to wait on lines. The platform also allows retail grocers to direct shoppers to discounted products with in-store promotions and collects valuable in-store shopping data to optimize operations and inventory management.

08:36 EDT BioMarin announces updated results from Phase 1/2 study of valoctocogene - BioMarin Pharmaceutical announced updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. The Company plans to share the data during an oral presentation at the upcoming International Society on Thrombosis and Haemostasis, or ISTH, 2022 Congress. Six-year and five-year post-treatment follow-up of the 6e13 vg/kg and 4e13 vg/kg cohorts, respectively, demonstrated sustained hemostatic efficacy of valoctocogene roxaparvovec. All participants in the 6e13 vg/kg cohort remain off prophylactic Factor VIII treatment at the time of the data cut. The mean cumulative annualized bleed rate (ABR) remains less than one and substantially below baseline levels; the mean ABR in year six was 0.7 with a mean cumulative ABR reduction of 95% and Factor VIII use reduction of 96% through six years, compared to baseline. BioMarin plans to include the previously reported results from the two-year follow-up safety and efficacy data from the Phase 3 GENEr8-1 study in a Biologics Licensing Application resubmission for valoctocogene roxaparvovec to the FDA. Overall, the safety profile of valoctocogene roxaparvovec in the Phase 1/2 study remains consistent with previously reported data with no delayed-onset treatment related adverse events.

08:35 EDT DexCom says 'not in active discussions regarding a merger transaction' - DexCom (DXCM) issued the following statement in response to recent media and market speculation: "Like many companies, Dexcom's Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change." Bloomberg had reported last week that CGM maker Dexcom was in talks to buy insulin pump maker Insulet (PODD).

08:35 EDT 180 Life begins consultations with UK, US authorities for Dupuytren treatment - 180 Life Sciences announced, following publication of promising data from a Phase 2b Dupuytren's trial in the June 2022 issues of The Lancet Rheumatology, that 180 Life Sciences has initiated preliminary consultations with regulatory agencies in both the UK and USA, with the assistance of Kinexum, the Company's regulatory advisor. At a scientific advice meeting with the Medicines and Healthcare products Regulatory Agency, UK MHRA, on May 18, 2022, the Company presented the results of the Phase 2b trial and received guidance on the path forward for further development. The Company awaits formal feedback from UK MHRA. The U.S. Food and Drug Administration, FDA, has agreed to provide a written response to the Company's briefing materials including the results of the Phase 2B trial, on a Type C meeting request. Guidance from the FDA is expected to shape the Company's clinical development strategy in the USA. "We believe our recent results present the potential for an earlier treatment for patients with Dupuytren's disease, which is easy to diagnose at an early stage," said James Woody, M.D., Chief Executive Officer of 180 Life Sciences, who continued, "We look forward to feedback from the regulatory agencies which we believe may help us bring this potential treatment to patients to prevent the disease from advancing to the stage that surgery is needed to maintain hand function."

08:34 EDT DexCom says 'not in active discussions regarding a merger transaction'

08:32 EDT Alexandria Real Estate raises quarterly dividend to $1.18 from $1.15 per share - Alexandria Real Estate Equities announced that its Board of Directors declared a quarterly cash dividend of $1.18 per common share for the second quarter. The dividend is payable on July 15 to shareholders of record on June 30. The common stock dividend for the 12 months ending June 30 of $4.60 per common share represents an increase of 24c, or 6%, over the 12 months ended June 30, 2021.

08:30 EDT Mana Capital Acquisition Corp trading resumes

08:27 EDT SmileDirectClub appoints Williams to board of directors - SmileDirectClub announced the appointment of Linda Williams as an independent director on its Board of Directors. Her appointment as an independent director will be effective June 3, 2022, immediately following the Company's annual meeting of stockholders to be held on the same date. Williams currently serves as the Senior Vice President and Chief Risk and Audit Executive at Blue Cross Blue Shield of Massachusetts where she leads audit efforts and provides oversight of investments and enterprise level business risks including cybersecurity.

08:26 EDT Outlook Therapeutics: FDA requests more information on ONS-5010 BLA - Outlook Therapeutics announced that the U.S. FDA has requested additional information in order to complete the filing of the company's Biologics License Application for ONS-5010/ LYTENAVA for the treatment of wet age-related macular degeneration. Outlook Therapeutics has voluntarily withdrawn its BLA for ONS-5010 and is actively working to respond to the FDA's request. The Company plans to re-submit a revised BLA by September 2022. Russell Trenary, President and CEO of Outlook Therapeutics, commented, "We remain confident in ONS-5010 and its potential to be the first FDA-approved ophthalmic formulation of bevacizumab that avoids the public health risk to patients of off-label treatment of bevacizumab that was never approved for any ophthalmic indications. We are continuing to have productive discussions with the FDA and are committed to providing the additional information necessary to support the application. We look forward to a successful resubmission and ultimately the potential approval of ONS-5010 for the treatment of wet AMD. We also look forward to a future where virtually all retina patients treated with bevacizumab are receiving an FDA-approved ophthalmic therapy." Based on a compilation of the data from its previously completed clinical trials - NORSE ONE, NORSE TWO and NORSE THREE - Outlook Therapeutics submitted the BLA to the FDA in March 2022. NORSE ONE, a proof-of-concept and clinical experience trial, helped validate the protocols and approach for NORSE TWO, the pivotal safety and efficacy trial. The NORSE TWO data were statistically significant and clinically relevant for the primary and all secondary endpoints. NORSE THREE was an open-label supplementary safety trial conducted to ensure that a sufficient number of patients had been dosed with ONS-5010 ophthalmic bevacizumab to support the regulatory submission.

08:24 EDT Esperion announces five abstracts accepted for presentation at NLA 2022 - Esperion announced five abstracts have been accepted for presentation at the National Lipid Association Scientific Sessions, NLA 2022 Scientific Sessions, being held in-person in Scottsdale, Arizona. "In the wake of the pandemic, the US is in serious risk of moving backward on critical public health initiatives like maintaining a healthy cholesterol and metabolic profile. We believe Esperion is uniquely positioned to help address this issue with our approved therapies," said Sheldon Koenig, president and chief executive officer of Esperion. "That is one reason we are presenting our real-world analysis on the major gaps in cardiovascular and metabolic care in advance of readouts from our upcoming pivotal CLEAR Outcomes study."

08:21 EDT Enlivex data shows improvements in survival with Allocetra, anti-PD1 - Enlivex Therapeutics announced new preclinical data from an ovarian cancer study conducted in collaboration with Yale Cancer Center. The study showed substantial and statistically significant improvements in survival benefit, survival duration and tumor burden reduction when Allocetra was combined with an anti-PD1 checkpoint inhibitor. The data will be featured in an upcoming poster presentation at the ASCO Annual Meeting, which is taking place both virtually and in-person at the McCormick Place convention center in Chicago, Illinois from June 3 - 7, 2022. The upcoming ASCO poster will also highlight a prior preclinical study in mesothelioma cancer that showed a substantial survival benefit when Allocetra was combined with a commercially approved anti-CTLA4 checkpoint inhibitor. Previously reported preclinical data in peritoneal cancer that show a substantial survival benefit when Allocetra is combined with chimeric antigen receptor T-cell therapy will also be presented.

08:20 EDT Pyxis Tankers regains compliance with Nadaq's minimum bid price requirement - Pyxis Tankers announced that it has regained compliance with the minimum bid price requirement under the continued listing requirements of the Nasdaq Stock Market. On May 27, 2022, the company received a written notification from Nasdaq's Listing Qualifications Department stating that the closing bid price of the company's common shares has been $1.00 per share or higher for ten consecutive trading days, from May 13, 2022 to May 26, 2022. Accordingly, the company has regained compliance with the exchange's minimum bid price rule. Separately, the company continued its mixed chartering strategy with three of its medium range product tankers employed in the spot market and two of its MR tankers employed under short-term time charters. Chartering conditions remain robust, and as of May 30, 2022, approximately 77% of the company's available days in second quarter of 2022 were booked for the Company's MR tankers at an average estimated daily Time Charter Equivalent rate of approximately $27,500.

08:18 EDT Mayfair Gold's Fenn-Gib Canada's first carbon neutral gold project - Mayfair Gold announces that the 100 percent controlled Fenn-Gib Projec is now Canada's first carbon neutral gold project following the completion of carbon offset purchases to account for emissions from Company-wide activities undertaken during 2021, the Company's first year of operations. Located in the Timmins region of Northeast Ontario, Fenn-Gib hosts a NI43-101 Indicated Resource of 2.08M ounces with disseminated gold mineralization striking east-west on the Pipestone Fault over 1.25 kilometers and up to 300 meters wide at the west end. Mayfair Gold President and CEO Patrick Evans commented: "Gold is Canada's most valuable mined commodity, valued in excess of $12 billion annually. The industry is a significant driver of economic activity across Canada, directly employing approx. 400,000 Canadians and offering the highest average annual industrial rate of pay in the country. The future of the industry depends critically upon sustainable development. At Fenn-Gib, we are laying the foundation for Canada's first carbon neutral gold mine. Our commitment started on January 1, 2021, when Mayfair acquired Fenn-Gib, and will continue through our exploration program, mine development, operations and eventual closure."

08:18 EDT Cardio Diagnostics to become public through Mana Capital Acquisition deal - Cardio Diagnostics and Mana Capital Acquisition (MAAQ) announced that they have entered into a definitive business combination agreement that will result in Cardio Diagnostics becoming a publicly listed company. Upon closing of the transaction, Mana will be renamed Cardio Diagnostics and it expects to remain listed on the Nasdaq Global Market under a new ticker symbol (CDIO). Founded in 2017, Cardio Diagnostics' mission is to help physicians better detect and treat cardiovascular disease, the leading cause of death in the United States. At the core of the company's cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine created at the University of Iowa by company founders Meesha Dogan and Rob Philibert. This technology enables the development of a series of tests for precision prevention, early detection, and assists in personalized treatment of major types of cardiovascular diseases and associated co-morbidities. Cardio Diagnostics' flagship product, Epi+Gen CHD, is a clinical test that was recently commercialized to assess the three-year risk for coronary heart disease, the most common type of heart disease and the primary cause of heart attacks. This highly sensitive and accessible test that profiles a panel of genetic and epigenetic biomarkers is radiation-free, does not require fasting and is associated with cost savings per quality-adjusted life year and improved survival. The combined company is expected to have an approximate post-transaction equity market capitalization of $175M assuming no redemptions. Cardio Diagnostics is expected to have approximately $10M in gross proceeds raised in 2022 from common stock equity investors prior to closing. Cardio Diagnostics' cash on the balance sheet prior to closing is expected to fund the combined company's operations through the end of 2023; net proceeds raised in conjunction with the transaction will be used to support the growth strategy. Current Cardio Diagnostics management, employees and existing shareholders will roll 100% of their existing equity holdings into equity of the combined company. Depending on levels of redemptions, existing Cardio Diagnostics security holders will receive between 52% and 85% of the pro forma equity as part of the transaction. The business combination has been approved by the boards of directors of both Mana and Cardio Diagnostics, and is expected to close in the second half of 2022, subject to regulatory and stockholder approvals and other customary closing conditions.

08:16 EDT Lexicon resubmits NDA for Sotagliflozin for treatment of heart failure - Lexicon Pharmaceuticals announced that it has resubmitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. "The resubmission of our NDA places us a step closer to the possibility of bringing this innovative new investigational treatment to heart failure patients," said Lonnel Coats, Lexicon's chief executive officer. "We believe sotagliflozin's dual SGLT1 and SGLT2 mechanism and the data from our SOLOIST-WHF and SCORED Phase 3 trials address important areas of need in the treatment of heart failure. We look forward to working closely with the FDA during the review process." The NDA submission is supported by the results from the Phase 3 SOLOIST-WHF clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease.

08:14 EDT Timber Pharmaceuticals receives FDA Breakthrough Therapy designation to TMB-001 - Timber Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation to TMB-001, a topical isotretinoin formulated using the Company's patented IPEG delivery system, for the treatment of congenital ichthyosis, CI. "This is a significant moment for people who are living with CI, their families and caregivers, and clinicians and researchers who have been working for years to find new treatment options for this debilitating condition," said John Koconis, Chairman and Chief Executive Officer of Timber. "A Breakthrough Therapy designation is no small achievement. Through half of FDA's 2022 fiscal year, more breakthrough applications have been rejected by FDA or withdrawn (16), than have been granted (9). I am proud of our team for demonstrating the potential of TMB-001 in our Phase 2b program, and we are rapidly pushing forward with a pivotal Phase 3 clinical trial." Timber is developing TMB-001 for the treatment of moderate to severe forms of CI, including X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis lamellar ichthyosis. CI is a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. In patients with XRI and ARCI-LI, cutaneous manifestations include large, dark scaling throughout the body.

08:13 EDT SI-Bone receives FDA 510(k) clearance for iFuse Bedrock Granite - SI-BONE announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System. The Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. This clearance follows the earlier designation by the Food & Drug Administration, FDA, of Granite as a Breakthrough Device, BDD, and most recently, a proposal by the Centers for Medicare and Medicaid Services, CMS, for a New Technology Add-on Payment, NTAP. CMS has also issued new technology "Section X" ICD-10 unique procedure coding for hospitals to report NTAP eligible cases that use Granite as an Internal Fixation Device with Tulip Connector, for either open or percutaneous sacroiliac joint fusion and sacropelvic fixation. "We are thrilled to receive FDA 510(k) clearance to launch Granite to the market. The anticipation has been building ever since the FDA awarded BDD for its promise of providing more effective treatment than the current standard of care, and CMS' recently proposed NTAP, recognizing it as a new technology that can provide substantial clinical improvement over already available therapies," said Laura Francis, CEO of SI-BONE. "Based on the early pre-clinical data from in vivo animal studies suggesting significant bone ingrowth and superior mechanical stability, internal studies showing markedly improved biomechanics, and initial feedback from surgeons, we couldn't be more enthusiastic about Granite's clinical and commercial promise as a uniquely disruptive technology."

08:11 EDT Janux announces FDA clearance of JANX007 IND for mCRPC treatment - Janux Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's investigational new drug application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer. JANX007 is the Company's lead novel T cell engager therapeutic from its TRACTr platform. Janux plans to initiate a Phase 1 clinical trial for JANX007 in the second half of 2022. "We are proud to announce today the clearance of Janux's first IND - a critical milestone for our TRACTr platform and for the Company as we advance a broad pipeline of next generation immunotherapies to address unmet needs and improve the treatment of cancer," said David Campbell, Ph.D., President and CEO of Janux. "JANX007 is uniquely designed to overcome the clinical limitations of existing TCE approaches, potentially providing mCRPC patients a safer therapeutic option, while also generating potent anti-tumor activity by enabling the delivery of a higher concentration of active drug. With this IND acceptance, we are on track to advance JANX007 into the clinic in the second half of this year." Unlike existing TCE approaches to prostate cancer that have been limited to-date by dose-limiting toxicities, poor pharmacokinetic profiles and attenuated efficacy, JANX007 is designed as a safer, highly potent anti-tumor approach to mCRPC. In preclinical studies, JANX007 was well tolerated in non-human primates with limited healthy tissue toxicities and cytokine release syndrome and exhibited enhanced safety and PK properties relative to unmasked TCEs. These data along with the superior manufacturability properties of JANX007 support its further development as an attractive mCRPC therapeutic.

08:11 EDT Enphase Energy expands home solar, battery storage deployments in Germany - Enphase Energy announced that installers of Enphase products in Germany have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries. This growth comes as the region faces rising energy prices and growing demand for electrification. Enphase announced the launch of the IQ Battery in Germany last June, the product's first market expansion outside of the United States. Enphase also recently announced that IQ Batteries will now support third-party inverters in Europe, further enabling the growth of Enphase's business in Germany to help meet installer and homeowner needs for a safe and reliable all-in-one home energy solution. This growth in Germany will be further supported by Enphase's strategic agreements with several installation partners, including German climate tech startup 1KOMMA5. The partnership with 1KOMMA5 aims to extend Enphase's footprint in Germany and other European markets while also extending energy trading benefits to Enphase's customers via 1KOMMA5 virtual power plant applications.

08:10 EDT Nasdaq confirms continued listing of Eargo stock - Eargo announced that it received a letter from The Nasdaq Stock Market LLC dated May 26, 2022 informing Eargo that the company's filing delinquency for the period ended March 31, 2022 has been cured, that the scheduled hearing on June 16, 2022 has been cancelled, that the Nasdaq matter regarding the listing of Eargo's securities is now closed and that Eargo's stock will continue to be listed and traded on Nasdaq. The letter from Nasdaq follows the company's filing on May 24, 2022 of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which made the company current in its filing obligations with the U.S. Securities and Exchange Commission. Christian Gormsen, President and CEO, said, "Becoming current on our SEC filings is yet another example of our people's tenacity. We are thrilled to achieve this milestone and excited to continue focusing on our operational execution, growth, and passion to help more people hear better."

08:10 EDT Aadi Bioscience appoints Graham as SVP, IR, Corporates Communications - Aadi Bioscience (AADI) announced the appointment of Marcy Graham to the new position of Senior Vice President, SVP, Investor Relations, IR, and Corporate Communications. Graham brings more than 20 years of biotech and pharma-specific investor relations and corporate communications experience, leading these functional areas at companies in all stages of development. She joins Aadi after most recently serving as the Vice President of Corporate Affairs at Poseida Therapeutics (PSTX).

08:08 EDT Gritstone announces updates OS results from Phase 1/2 study of GRANITE - Gritstone bio (GRTS) announced updated overall survival, OS, results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy, to treat advanced solid tumors. Additionally, the company announced it is presenting a "Trial in Progress" poster summarizing the Phase 2/3 GRANITE-CRC-1L- study at the 2022 American Society for Clinical Oncology, ASCO, Annual Meeting. The Phase 1/2 study is evaluating the safety, immunogenicity, and clinical activity of GRANITE in combination with PD-1 checkpoint inhibitor, Opdivo and subcutaneous anti-CTLA-4 antibody, Yervoy in advanced solid tumors. This study enrolled and treated 26 patients as of ESMO 2021 presentation with previously treated, metastatic solid tumors including patients with colorectal cancer, gastroesophageal adenocarcinoma, and non-small cell lung cancer. As presented at ESMO 2021, of 9 patients with MSS-CRC who were treated and evaluable for molecular response, 4 experienced a molecular response and continue to have an OS advantage compared to those patients who did not have a molecular response. Opdivo and Yervoy are trademarks of Bristol-Myers Squibb Company (BMY). Updated overall survival data from GRANITE Phase 1/2: 4 of 9 treated patients with MSS-CRC had a molecular response and the observed median overall survival in this group will now exceed 18 months. All patients with MSS-CRC assessed for molecular response and alive at the time of the ESMO 2021 data presentation remain alive after an additional 35 weeks of follow-up.

08:06 EDT VolitionRx's Nu.Q NETs achieves CE mark for detection and evaluation of NETosis - VolitionRx has announced that its Nu.Q NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe. NETosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps, or NETs, composed of decondensed chromatin, that trap and kill bacteria and viral particles. Although NETs play an important role in our immune system, excessive production can lead to tissue damage and, in severe cases, sepsis, shock, and death.

08:05 EDT Leidos unit awarded two prime contracts worth up to $1.7B - QTC Medical Services, a Leidos company, was recently awarded two prime contracts to provide medical disability examination services to both veterans and separating or retiring service members. The indefinite delivery/indefinite quantity, firm-fixed-price contracts were awarded by the Veterans Benefits Administration, Medical Disability Examination Office. The contracts each have six-month base periods of performance with six one-year options and a combined estimated value of $1.7B, if all options are exercised.

08:03 EDT Abbott announces FDA cleared its FreeStyle Libre 3 system - Abbott announced the FDA cleared its FreeStyle Libre 3 system for use by people four years and older living with diabetes. FreeStyle Libre 3 System Features: Greatest accuracy, with a 7.9% overall mean absolute relative difference, the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor with readings sent directly to a smartphone every minute. It's the first CGM to demonstrate a sub-8% MARD1,6 - which is the standard way to measure continuous glucose accuracy - the lower percentage, the better. Smallest and thinnest - at the size of two stacked U.S. pennies, it's the smallest and thinnest4,7 CGM sensor in the world. Even easier to use - with a one-piece applicator the sensor is uncomplicated to apply. Strongest Bluetooth integration with a range of up to 33 feet - 50% further range than other CGMs.4,8.

07:55 EDT Mana Capital Acquisition Corp trading halted, news pending

07:44 EDT Guardforce receives notification letter from Nasdaq Stock Market - Guardforce AI announced that it has received a notification letter from the Nasdaq Stock Market dated May 27, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ. This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from April 14, 2022 through May 26, 2022 the Company no longer meets the minimum bid price requirement. In accordance with the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until November 23, 2022, to regain compliance with NASDAQ Listing Rule 5550(a)(2).

07:42 EDT Theratechnologies announces new Head of Investor Relations - Theratechnologies announced that Elif McDonald has joined the team as Senior Director, Investor Relations. McDonald brings experience earned over 20 years in capital markets, investor relations, financial communications, and corporate governance.

07:39 EDT PyroGenesis announces completes another commercial order - PyroGenesis Canada announces that the Company has received, and completed, another commercial order for its plasma atomized titanium powders for 3D printing. "This latest order, for 100kg, represents the second consecutive commercial batch of metal powders produced using the Company's NexGen plasma atomization system, at our state-of-the-art production facility in Montreal, in as many weeks," said Massimo Dattilo, VP, PyroGenesis Additive. "We are excited to release this second 100kg batch so soon after the first. Creating the NexGen plasma atomization process, to produce the highest quality metal powders in the additive manufacturing industry, has been a long and exacting journey," continued Dattilo. "As mentioned in our previous press release, we are now producing larger commercial batches measuring in hundreds of kilograms, as opposed to sample batches measured in grams. The commercial milestones we have achieved over the previous few months have positioned us to move to the next step, which is to produce powders by the tonne."

07:36 EDT Lilium achieves main wing transition - Lilium announced that its technology demonstrator Phoenix 2 has achieved main wing transition. This means it is the first ever full-size electric jet aircraft to transition from hover to wing-borne flight. "This is a landmark moment for Lilium and for electric aviation as a whole," the company said. Phoenix 2 has now achieved this milestone across the entire main wing while, most importantly, remaining stable and behaving as predicted by Lilium's proprietary Flight Dynamics Model. Matthias Meiner, Phoenix Chief Engineer and Lilium Co-Founder of Lilium said: "Main wing transition is a huge step forward on our path to launch and it validates our Flight Dynamics Model. Full credit goes to the outstanding Lilium team who worked so hard to get us here, and who remain laser-focused on the rest of the Flight Test Campaign.

07:35 EDT Marathon Gold makes engineering, construction management appointments - Marathon Gold provides an update on project execution planning at the Valentine Gold Project located in central Newfoundland. Marathon announces that is has signed a Letter of Intent with SNC-Lavalin to complete detailed engineering for the Project's mill and major facilities, and develop related equipment and construction packages. SNC-Lavalin is a fully integrated professional services and project management company with offices around the world that has particular experience in the engineering and delivery of mineral processing projects. Marathon further announces the appointment of Progesys to partner with Marathon in the development of an integrated construction management team. Progesys will provide project management, facilities construction, and project control services. The Progesys-Marathon construction team will continue through to the operational readiness and commissioning phases of the Project until delivery to a Marathon operating team.

07:34 EDT Superior Group appoints Koempel as CFO - Superior Group of Companies announces that the Board of Directors of the Company has appointed Michael Koempel to the role of Chief Financial Officer, CFO, of the Company, effective May 31, 2022. Most recently, Koempel was chief operating officer of IT'SUGAR. Koempel will report directly to SGC's Chief Executive Officer, Michael Benstock. Alongside the hiring of Koempel comes the announcement that Andrew Demott, Jr. will resign as Chief Financial Officer, effective May 31, 2022, but will remain with the Company as its Chief Operating Officer and as a Director. Demott intends to retire as an employee in 2023.

07:32 EDT Brooklyn ImmunoTherapeutics announces changes to executive management - Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer. Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience as CEO since its founding in 2011. Jackson joins the Company from Ra Medical Systems (RMED), a medical device company focused on vascular diseases where he served as its Chief Financial Officer and Secretary and for a period, its Interim Chief Executive Officer.

07:21 EDT SpartanNash shareholder announces ISS recommendation for its proxy card - Macellum Advisors and Ancora Holdings, who beneficially own approximately 4.5% of the outstanding common shares of SpartanNash announced that Institutional Shareholder Services, or ISS, an independent proxy advisory firm, has recommended the company's shareholders vote for boardroom change on the blue proxy card. In particular, ISS recommends the addition of two of the investor group's nominees - Michael Lewis and John Fleming - to SpartanNash's board of directors. Jonathan Duskin, managing partner of Macellum, and Fredrick DiSanto, chairman and CEO of Ancora, commented: "We are pleased that ISS has endorsed our case for change at SpartanNash and recommended shareholders vote on the BLUE proxy card to elect two of our highly qualified, independent director candidates to the Company's nine-member Board. In our view, ISS' recommendation validates our thesis that the current Board lacks the operational knowhow, industry expertise and shareholder perspective required to unlock the Company's full potential. It is particularly notable that ISS affirmed our view that leadership's reactionary three-year plan includes targets that are meager and fall short of what shareholders deserve over the long run. Indeed, shareholders have already suffered through years of financial and operational underperformance."

07:14 EDT Zealand Pharma announces multiple presentations at ADA Scientific Sessions - Zealand Pharma announced that three oral presentations and two poster abstracts with Zealand Pharma products have been accepted for the upcoming 82nd Scientific Sessions of the American Diabetes Association, ADA, which is being held in New Orleans from June 3-7, 2022. Zealand Pharma has two oral presentations, including Phase 1 clinical data demonstrating significant weight loss with Zealand's dapiglutide, a novel GLP1/GLP2 dual agonist and preclinical data on the antidiabetic potential of the company's long-acting amylin analogue ZP8396. Zealand also has a poster presentation with preclinical data highlighting the weight loss effects of ZP8396. Two additional abstracts include study results from a Zealand supported, investigator-initiated trial with dasiglucagon led by investigators from the Steno Diabetes Center. This oral presentation reports novel data on the use of low dose dasiglucagon for prevention and treatment of non-severe hypoglycemia in people with type 1 diabetes. Additionally, Boehringer Ingelheim will have a poster presentation with preclinical data on the dual glucagon and glucagon-like peptide-1 receptor agonist BI 456906 co-invented with Zealand Pharma, for the treatment of obesity.

07:12 EDT Equinox Gold receives approval for TSF raise at RDM Mine in Brazil - Equinox Gold announces that further to its press release dated May 16 approval for the tailings storage facility, or TSF, raise at its RDM Mine in Brazil has been received. The TSF raise contractor is mobilizing equipment to begin the raise in early June. Equinox Gold expects that full operations will resume by mid-July. Equinox Gold will update RDM guidance with its Q2 disclosures in the first week of August.

07:10 EDT Hasbro board issues letter to shareholders ahead of June 8 meeting - Hasbro issued the following letter to Hasbro shareholders in connection with the Company's 2022 annual meeting of shareholders to be held on June 8. "As we approach the last few days leading up to Hasbro's Annual Meeting of Shareholders, taking place June 8 we ask you to vote the WHITE proxy card and "FOR ALL" the nominees proposed by the Hasbro Board... With our newly appointed CEO, Chris Cocks, we are charting Hasbro's next chapter of growth and success. Chris, together with Liz Hamren and Blake Jorgensen - each of whom have joined the Board in the last couple of months - bring depth of expertise, talent and informed points of view about our business. They have been change agents with a track record of delivering value. Their new perspective, combined with the depth of experience of our other board members, provide the right combination of skills and experience, and also stability and context, to position Hasbro to deliver long-term value and returns for our shareholders."

07:09 EDT PolyPid announces completion of enrollment in Phase 3 SHIELD I trial - PolyPid announced the completion of enrollment in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections, SSIs, in abdominal surgery. Following a review of unblinded efficacy data from the first 750 enrolled patients in the trial, the independent Data Safety Monitoring Board, DSMB, recently recommended concluding the study upon enrollment of 950 patients, which is the minimum number of targeted patients in the trial protocol. "The conclusion of enrollment in the pivotal SHIELD I trial, the largest colorectal surgery clinical study conducted in more than a decade, represents an important milestone for our D-PLEX100 development program and our company as a whole," stated Amir Weisberg, PolyPid's Chief Executive Officer. "We look forward to the availability of top-line results from SHIELD I by the end of the third quarter of 2022. Subsequent to these expected data, we intend to pursue a pre-NDA meeting with the FDA to discuss a rolling NDA submission, consistent with the Breakthrough Therapy Designation previously granted, with potential NDA and MAA submissions planned for the first half of 2023. We are also focused on further advancing commercial pre-launch activities, while expediting partnership discussions in and outside of the United States."

07:07 EDT Tela Bio secures up to $50M in debt financing from MidCap Financial - TELA Bio announced that the Company has entered into a new credit facility with MidCap Financial, providing TELA with access to up to $50M in total credit. A portion of the proceeds from the new credit facility were used to fully repay TELA's existing $30M credit facility with OrbiMed Royalty Opportunities II, LP, with the remaining proceeds under the credit facility available for working capital needs and other corporate purposes. "We are excited about our new partnership with MidCap which provides TELA with cost-effective funding and financial flexibility. This transaction is reflective of TELA's strong financial condition and prospects, which enabled us to access the debt capital markets to obtain non-dilutive financing," said Antony Koblish, president and CEO of TELA Bio. "The proceeds from this loan will allow TELA to fund its current key business objectives and drive future growth initiatives, with minimal further capital required to be raised, if at all."

07:06 EDT Allied Motion acquires FPH Group, terms of were not disclosed - Allied Motion Technologies announced that it has acquired FPH Group an industry participant in developing technically advanced, reliable and cost-effective electrical drive systems and light weighting technologies for existing and future ground-based vehicles in the defense industry. "This acquisition is an excellent strategic fit as it provides us with a deeper penetration within defense applications including the necessary manufacturing licenses and certifications, which is a key end market focus for Allied. FPH has a proven relationship with leading defense prime contractors, which we believe we can leverage for future modernization designs as we combine Allied's scale and defense solutions with FPH's knowledge base of electrical, mechanical, fluid dynamics and composite technologies," commented Dick Warzala, Chairman and CEO. "In addition, FPH is expected to be accretive to both Allied's margin profile and earnings per share in the first year. We are very excited about our potential together and we welcome the entire, very capable FPH team to the Allied family." Barry Gilmour, Chairman of FPH, stated, "Joining forces with Allied will enhance our ability to advance our core competencies in support of our existing customers and provide a platform to further scale the business. Equally important is that our companies share similar cultures, and we look forward to a bright future together." Financial terms of the transaction were not disclosed.

07:05 EDT TScan Therapeutics announces FDA clearance of IND application for TSC-101 - TScan Therapeutic announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, application to evaluate TSC-101 for the treatment of patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation, HCT. The target of TSC-101 is the minor histocompatibility antigen HA-2, which is a lineage-specific antigen expressed on blood cells. TScan believes that TSC-101 is the first clinical program to target the HA-2 antigen. As previously announced, TScan's IND for TSC-100, which targets the minor histocompatibility antigen HA-1, was cleared by the FDA in January 2022. TSC-100 and TSC-101 are designed to address different subsets of patients undergoing allogeneic HCT. "This marks TScan's second IND clearance in our leukemia program. Our TCRs against both HA-1 and HA-2 antigens are aimed at reducing the risk of relapse following HCT, thereby enabling increased use of more tolerable conditioning regimens to allow more leukemia patients to be cured by transplantation," said David Southwell, President and Chief Executive Officer. "With the FDA clearance of TSC-101, we will now proceed with all components of our planned multi-arm Phase 1 clinical trial, with preliminary data from all three arms of the trial expected by the end of 2022."

07:03 EDT Axsome Therapeutics announces publication of results of Phase 3 trial of AXS-05 - Axsome Therapeutics announced the publication on May 30 of the results from the pivotal GEMINI Phase 3 clinical trial of AXS-05 in major depressive disorder. AXS-05 is a novel, oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity. The article, "Efficacy and Safety of AXS-05 (dextromethorphan-bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial," was published in The Journal of Clinical Psychiatry. "The results published in The Journal of Clinical Psychiatry are consistent with strong and rapid antidepressant effects, and with a favorable safety profile with AXS-05," said Maurizio Fava, MD, Psychiatrist-In-Chief, Department of Psychiatry, Massachusetts General Hospital, Executive Director, Clinical Trials Network & Institute, Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School, and co-author of the publication. "Depression is a difficult-to-treat condition with potentially devastating consequences for patients and their families. Based on these results and its novel oral NMDA antagonist mechanism, AXS-05 may represent an important new treatment option for patients with depression." "We are very pleased with the publication of the pivotal GEMINI trial results in The Journal of Clinical Psychiatry, a leading scientific journal, less than two weeks after the publication of the pivotal ASCEND trial results in The American Journal of Psychiatry," said Herriot Tabuteau, MD, CEO of Axsome. "These studies demonstrate a consistent efficacy profile for AXS-05 and form the basis of our NDA for the treatment of depression. If approved, we look forward to making AXS-05 available to Americans suffering from depression as soon as possible."

06:57 EDT Rayonier Advanced Materials names De Lyle Bloomquist as CEO - Rayonier Advanced Materials announced that De Lyle Bloomquist has been appointed President and CEO of the company, effective immediately. Bloomquist succeeds Vito Consiglio, who has stepped down as President and CEO of the company, and as a member of the company's Board of Directors, with the mutual agreement of the Board. In connection with Bloomquist's appointment, the Board named Lisa Palumbo as Non-Executive Chair of the Board. Bloomquist most recently served as a partner at Windrunner Management Advisors LLC, a management advisory services business, and prior to that served as the President, Global Chemical Business of Tata Chemicals Limited, and President, CEO and Director of Tata Chemicals North America.

06:47 EDT Glass, Lewis & Co. recommends Preferred Apartment's stockholders to vote "FOR" - Preferred Apartment Communities announced that Glass, Lewis & Co., another leading independent proxy advisory firm, has joined Institutional Shareholder Services, or ISS, in recommending that stockholders vote "FOR" the previously announced all-cash acquisition of PAC by Blackstone Real Estate Income Trust, or BREIT, at PAC's upcoming Special Meeting of Stockholders scheduled for June 7 at 9:00 a.m., Eastern Time. As previously announced, PAC and affiliates of BREIT have entered into a definitive merger agreement pursuant to which BREIT has agreed to acquire PAC for $25.00 per share of common stock. The proposed acquisition is expected to be completed on or about June 9, subject to approval by PAC's common stockholders and the satisfaction or waiver of other customary closing conditions. PAC's Board of Directors recommends that you vote "FOR" the proposed acquisition of PAC by BREIT. All PAC stockholders of record as of the close of business on April 11, 2022 are entitled to vote.

06:41 EDT FDA approves Roche's Evrysdi for use in babies under two months with SMA - Roche announced that the U.S. Food and Drug Administration has approved a label extension for Evrysdi to include babies under two months old with spinal muscular atrophy, or SMA. The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment. Evrysdi is now approved in the U.S. to treat SMA in children and adults of all ages. As part of the label extension, the Evrysdi prescribing information has also been updated to include recent two-year pooled data from Parts 1 and 2 of the FIREFISH study, which demonstrate long-term efficacy and safety in symptomatic infants with Type 1 SMA. The study enrolled babies aged 1-7 months and after two years of treatment with Evrysdi at the recommended dose, 60% of infants were able to sit without support* for five seconds, 40% for 30 seconds and 28% of infants were able to stand, the company noted.

06:11 EDT Axonics files premarket approval supplement with FDA for its sacral INS - Axonics has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator, or INS. The fourth generation rechargeable INS reduces how frequently a patient needs to recharge their implanted device to only once every six months for one hour. This compares to the current recharging interval of once a month for one hour with the Axonics third generation rechargeable INS. The new INS utilizes the same small 5cc form factor as the Axonics R15 and is paired with the same tined lead and intuitive, easy to use patient remote control. Axonics expects the new INS to receive FDA labeling for 20 years of useful life in the body. Axonics anticipates receiving FDA approval for the fourth generation rechargeable INS in the Q4 and expects to begin shipping the new device to customers in the Q1 of 2023. This filing follows the recent FDA approval of the Axonics F15, the company's newly developed, long-lived, recharge-free system, which commenced a comprehensive U.S. commercial launch in April.

06:08 EDT Coda Octopus CFO Mike Midgley to retire, Nathan Parker to succeed - Coda Octopus Group announced the retirement of its current CFO, Mike Midgley who will formally leave his post in June 2022 and the appointment of Nathan Parker who will succeed Midgley as CFO, effective June 13. Parker will be based in Salt Lake City. Nathan Parker joins the Group as a well-qualified and experienced financial professional who will bring a number of additional skills to this role. From 2021 to 2022, Nathan was CFO for the Water Treatment business of Franklin Electric, a Fort Wayne Indiana based $2B global leading manufacturer and distributor of water and fuel systems for use across residential, commercial, agricultural, industrial, and municipal applications.

06:03 EDT PotlatchDeltic, CatchMark Timber to combine in an all-stock transaction - PotlatchDeltic (PCH) and CatchMark Timber Trust (CTT) announced that they have entered into a definitive agreement to combine in an all-stock transaction. The acquisition by PotlatchDeltic will strengthen and diversify a leading integrated timber REIT and continue to enhance shareholder value. Based on the closing stock prices of PotlatchDeltic and CatchMark on May 27, 2022, the combined company is expected to have a pro forma market capitalization over $4B and total enterprise value of more than $5B, including $557M in net debt. Under the terms of the agreement, which has been unanimously approved by the Board of Directors of both companies, CatchMark stockholders will receive 0.23 common shares of PotlatchDeltic stock for each common share of CatchMark that they own. This reflects a price per share of $12.88 for each common share of CatchMark, and a 55% premium to CatchMark's common share price as of the close of business on May 27, 2022. Following close of the transaction, PotlatchDeltic stockholders will own approximately 86% of the combined company, and CatchMark stockholders will own approximately 14% on a fully diluted basis. The combination brings together two high quality timberland REITs resulting in PotlatchDeltic owning approximately 2.2M acres of diversified timberlands including 626,000 acres in Idaho and over 1.5M acres in strengthening markets in the U.S. South. PotlatchDeltic also remains the timber REIT with the most leverage to lumber prices, including 1.1B board feet of lumber capacity. The transaction also combines two successful and complementary real estate businesses. The Board of Directors of the combined company will consist of nine Directors from PotlatchDeltic and one Director from CatchMark. The corporate headquarters will be maintained in Spokane, Washington. A regional office will be maintained in Atlanta, Georgia. The transaction is expected to close in the second half of 2022. The transaction requires approval of stockholders of CatchMark and is subject to the satisfaction of customary closing conditions and regulatory approvals. Due to the transaction, CatchMark has postponed the 2022 annual meeting of its stockholders that had been scheduled for June 14.

06:01 EDT PotlatchDeltic, CatchMark Timber to combine in an all-stock transaction

05:49 EDT GlaxoSmithKline to buy Affinivax in potential $3B deal - GSK announced that it has entered into a definitive agreement to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B upfront payment and up to $1.2B in potential development milestones. Affinivax is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines, GSK said in a statement. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: "The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area. We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialization capabilities to make this exciting new technology available to those in need." Under the terms of the agreement, GSK will acquire 100% of the outstanding shares of Affinivax. The consideration for the acquisition comprises an upfront payment of $2.1B to be paid upon closing and two potential milestone payments of $0.6B to be paid upon the achievement of certain paediatric clinical development milestones. The transaction is subject to customary closing conditions, including the expiration or early termination of the waiting period under the Hart-Scott- Rodino Anti-Trust Improvements Act of 1976. The transaction is expected to close in the third quarter of 2022.

05:24 EDT Argenx announces efgartigimod awarded scientific opinion by the MHRA - Argenx announced that efgartigimod, the company's neonatal Fc receptor, or FcRn, blocker has been awarded a scientific opinion by the MHRA under the EAMS. Within the EAMS, efgartigimod is indicated for the treatment of adult patients with anti-acetylcholine receptor, or AChR, antibody seropositive gMG, including patients with refractory gMG who have failed, not tolerated or are ineligible for licensed treatment. The European Medicines Agency is currently reviewing the MAA for efgartigimod for the treatment of gMG, with a decision expected in the second half of 2022, followed by an anticipated decision from the MHRA on a UK marketing authorization. Efgartigimod was previously granted a PIM designation by the MHRA in November 2021.

05:20 EDT Gold Fields to acquire Yamana Gold in $6.7B transaction - Gold Fields (GFI) and Yamana Gold (AUY), announced that they have entered into a definitive agreement, under which Gold Fields will acquire all of the outstanding common shares of Yamana pursuant to a plan of arrangement. Under the terms of the transaction, all of the outstanding Yamana Shares will be exchanged at a ratio of 0.6 of an ordinary share in Gold Fields or 0.6 of a Gold Fields American depositary share for each Yamana share. The transaction implies a valuation for Yamana of $6.7B and represents a premium of 33.8% to the 10-day Volume-Weighted Average Price, or VWAP, of Yamana's Shares of $5.201 on Friday, May 27, being the last trading day on the NYSE prior to the date of this announcement, based on the 10-day VWAP of Gold Fields ADSs of $11.592. Upon closing of the transaction, it is anticipated that Gold Fields shareholders and Yamana shareholders will own approximately 61% and 39% of the combined group, respectively. The combined group will maintain its presence in all regions while continuing to honor commitments to stakeholders. The transaction has been unanimously approved by the board of directors of both Gold Fields and Yamana and is expected to close in the second half of 2022 subject to and following the satisfaction of the conditions precedent to the transaction. Gold Fields will remain headquartered in Johannesburg. The acquisition will be implemented by way of a plan of arrangement of Yamana under the Canada Business Corporations Act, or CBCA, pursuant to the arrangement agreement entered into between Gold Fields and Yamana. The consideration payable to the shareholders of Yamana will consist of either, at the election of a Yamana shareholder, newly issued Gold Fields shares or newly issued Gold Fields ADSs, which each represent one Gold Fields Share, in accordance with the exchange ratio. The Gold Fields shares are listed on the Johannesburg Stock Exchange and the Gold Fields ADSs are listed on the NYSE. The board of directors of Gold Fields has unanimously approved the arrangement agreement. The board of directors of Gold Fields recommends that Gold Fields Shareholders vote in favor of the transaction. After consultation with its outside financial and legal advisors, the Board of Directors of Yamana has unanimously approved the Arrangement Agreement. The Board of Directors of Yamana recommends that Yamana Shareholders vote in favour of the Transaction. In addition, all of the Directors and Senior Officers of Yamana, have entered into binding voting support agreements with Gold Fields under which such individuals have agreed to support and vote their Yamana Shares in favour of the Transaction. The Board of Directors of Yamana has received fairness opinions from Canaccord Genuity Corp. and Scotiabank that, as of the date of each such opinion, and based upon and subject to the assumptions, limitations and qualifications stated in each such opinion, the Transaction Consideration to be received by Yamana Shareholders is fair from a financial point of view to Yamana Shareholders. The Transaction will be effected by way of a plan of arrangement under the CBCA, pursuant to which all of the Yamana Shares will be acquired by a wholly-owned indirect subsidiary of Gold Fields in exchange for the Transaction Consideration to be settled by Gold Fields in the form of the Gold Fields Consideration Shares. Pursuant to the terms of the Transaction, the consideration payable to the Yamana Shareholders at closing of the Transaction will consist of: either newly issued Gold Fields Shares; or at the election of Yamana Shareholders, newly issued Gold Fields ADSs, which each represent one Gold Fields Share together the "Gold Fields Consideration Shares"), in accordance with the Exchange Ratio. The Transaction will require the approval of at least 66 2/3% of the votes cast by Yamana Shareholders voting in person or represented by proxy at a special meeting of Yamana Shareholders called for that purpose. The issuance of Gold Fields Consideration Shares under the Transaction is also subject to the approval of at least 75% of the voting rights exercised on such resolution by Gold Fields Shareholders at a special meeting of Gold Fields shareholders called to approve the Transaction. The Transaction is subject to, among other things, the approval by the Ontario Superior Court of Justice (Commercial List), applicable stock exchange approvals and other regulatory approvals. The Arrangement Agreement includes reciprocal non-solicitation provisions (subject to provisions allowing the Board of Directors of each of Gold Fields or Yamana to exercise their fiduciary duties to change their recommendation and/or to enter into a permitted acquisition agreement in certain circumstances), and rights to match superior proposals. In addition, the Arrangement Agreement provides that, under certain circumstances, Gold Fields would be entitled to a US$300m termination fee and Yamana would be entitled to a US$450m termination fee. Senior officers and directors of each of Yamana and Gold Fields have entered into voting support agreements with Gold Fields and Yamana, respectively, agreeing to vote their Yamana Shares and Gold Fields Shares, respectively, in favour of the Transaction It is anticipated that both the Yamana and Gold Fields shareholder meetings will take place, and closing and completion of the transaction is expected to occur, in the second half of 2022, subject to satisfaction of the conditions under the arrangement agreement. Following the completion of the Transaction, the Gold Fields Shares will continue to trade on the JSE and the Gold Fields ADSs will continue to be listed on the NYSE, and the Yamana Shares will be delisted from each of the Toronto Stock Exchange, NYSE and London Stock Exchange.

05:09 EDT Unilever names Nelson Peltz non-executive director, shares rally 7% - Unilever announced the appointment of Nelson Peltz as a non-executive director of the company and as a member of its Compensation Committee. It is expected that the appointments will be effective from July 20. Nils Andersen, Chair of Unilever, said: "We are pleased to be welcoming Nelson to the Unilever Board. We have held extensive and constructive discussions with him and the Trian team and believe that Nelson's experience in the global consumer goods industry will be of value to Unilever as we continue to drive the performance of our business. We look forward to working closely together to create long term sustainable value for our shareholders and wider stakeholders." Peltz's Trian Fund Management has confirmed that it manages funds which hold interests in approximately 37.4M ordinary shares of Unilever, constituting approximately 1.5% of Unilever's share capital, the company noted. Shares of Unilever are up 7% to $47.08 following the news.